by Lauren Dubinsky
, Senior Reporter | October 19, 2016
On Tuesday, Royal Philips announced a partnership with PET imaging agent manufacturer, FluoroPharma Medical Inc., to provide data management for the Phase II clinical trials investigating its CardioPET agent.
CardioPET is an F-18-labeled, modified fatty acid that enters the heart the same way that natural fatty acids do, and can be used to assess the regions in the myocardium with decreased blood flow or metabolic insufficiency.
"It has been known for some time that a fatty acid tracer can detect coronary artery disease (CAD), specifically ischemia, based on work done with single-photon (SPECT) fatty acid molecules," Edward L. Lyons, Jr., vice president of development at FluoroPharma, told HCB News.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
FluoroPharma worked with Philips to put the image data generated by CardioPET through a quality assurance process. Philips' advanced molecular imaging technology was used to verify that the same standards were applied to data across clinical sites.
During an ischemic episode, the heart muscle's metabolism changes from fatty acids to glucose, to put the heart muscle in a "survival mode" until blood flow is adequately restored. Previous research has shown that abnormality can persist for up to 30 hours, which is called the ischemic memory.
"If CardioPET could identify ischemic memory, it could have implications for how we do stress testing; with or without exercise, for example," said Lyons.
The Phase II study was conducted in Belgium, and tested how well CardioPET can spot CAD in patients with SPECT scans that indicate the disease.
The researchers reported that there were no serious adverse events, and that the images showed evidence of CAD in patients who were confirmed to have the disease with SPECT and invasive angiography.
Going forward, FluoroPharma and Philips will work to improve image quality, and potentially design new approaches that are tailored to specific features of CardioPET.
“It is critical to ensure that the optimal image processing methodology is applied during the evaluation of performance of new radiotracers,” said Piotr Maniawski, director of clinical science, Advanced Molecular Imaging at Philips, in prepared remarks. “Working with FluoroPharma very early in the process of data collection and evaluation provides Philips with a unique opportunity to be a part of an effort aimed at improving molecular imaging in cardiology.”